Intranasal delivery of neutralizing antibodies for prophylatic COVID‑19 treatments
Technologies for passive immunity have the potential to decrease the transmission of SARS-CoV-2 in our communities and high-risk environments such as long term care homes. The intranasal delivery of virus neutralizing antibodies prior or soon after exposure to SARS-CoV-2 can prevent infection, which is a form of passive immunity. Therefore, intranasal delivery of neutralizing antibodies can prevent exposed individuals from getting sick and prevent the spread of disease. Passive immunity therapies are required as an alternative to vaccines, which may take multiple years to develop and fully implement. Furthermore, high risk populations such as the elderly have poor vaccine response rates, limiting their effectiveness.
To this end, we are developing delivery technologies to sustain the delivery of neutralizing antibodies for SARS-CoV-2 that can be administered through a simple nasal spray. Our goal is to decrease virus transmission in the community, which will allow for a greater quality of life and potentially eliminate the need for lockdowns.
